ReviewNature reviews. Rheumatology2014
The eye: a window of opportunity in rheumatoid arthritis?
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review.Journal of immunology research · 2021Pooled it
- Ultrasound-Guided Zhengqing Fengtongning vs Corticosteroid Injections for Plantar Fasciitis: A Randomized Controlled Trial on Short- and Long-Term Efficacy.Medical science monitor : international medical journal of experimental and clinical research · 2026Trial
- Ocular IL-1α/IFN-γ Delay the Corneal Wound Healing in Rheumatoid Arthritis Through Mitochondrial Dysfunction and NLRP3 Inflammasome Activation.Investigative ophthalmology & visual science · 2026Article
- An Overview of Rheumatoid Arthritis-Associated Dry Eye Disease, Scleritis, and Peripheral Ulcerative Keratitis.Journal of clinical medicine · 2026Review
- Janus kinase inhibitor use and incident dry eye disease in rheumatoid arthritis: a real-world cohort study.Frontiers in immunology · 2026Article
- Potential of Berberine for Rheumatoid Arthritis Prevention and Treatment.Chinese journal of integrative medicine · 2025Review
- Regulation of the innate immune response in rheumatoid arthritis.Frontiers in immunology · 2025Review
- Review
- Case report: Scleromalacia caused by rheumatoid arthritis combined with high intraocular pressure, first discovered due to ocular trauma.Frontiers in medicine · 2024Article
- Associations between vision impairment and multimorbidity among older Chinese adults: results from the China health and retirement longitudinal study.BMC geriatrics · 2023Article
- Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.Biomedicines · 2023Review
- The Autoimmune Rheumatic Disease Related Dry Eye and Its Association with Retinopathy.Biomolecules · 2023Review
- Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis.Scientific reports · 2023Article
- Rheumatoid Arthritis Associated with Dry Eye Disease and Corneal Surface Damage: A Nationwide Matched Cohort Study.International journal of environmental research and public health · 2023Article
- [Association of the different forms of uveitis with inflammatory rheumatic diseases and their treatment].Zeitschrift fur Rheumatologie · 2022Review
- A Rare Occurrence of Scleromalacia Perforans With Juvenile Rheumatoid Arthritis: A Case Report.Cureus · 2022Article
- Low-Concentration (0.66%) Povidone Iodine Treatment of a Corneal Ulcer in a Rheumatoid Arthritis Patient.The American journal of case reports · 2021Article
- Rethink About the Role of Rheumatoid Factor and Anti-citrullinated Protein Antibody in Rheumatoid Arthritis.Rheumatology and immunology research · 2021Review
- Dry eye in rheumatoid arthritis patients under TNF-inhibitors: conjunctival goblet cell as an early ocular biomarker.Scientific reports · 2020Article
- Adjunctive role of self-retained cryopreserved amniotic membrane in treating immune-related dry eye disease.International ophthalmology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA), the most common autoimmune disorder associated with dry eye syndrome, is also associated with sight-threatening ocular diseases such as peripheral ulcerative keratitis, scleritis and corneal melts. Tissue damage on the ocular surface of patients with RA is autoimmune-mediated. Findings from patients with dry eye have implicated defects in innate immunity (Toll-like receptors, S100A and resident antigen-presenting cells), cytokines, chemokines and T helper (TH)-cell subsets (including TH1 and TH17) in disease pathogenesis. Some of these features are probably important in dry eye related to RA, which can occur at a different time from articular disease and is more clinically severe than idiopathic dry eye. Ocular surface immune factors can be influenced by the systemic immune landscape. Depending on the severity of ocular inflammation in RA, treatment can include ciclosporin, topical corticosteroids, tacrolimus, autologous serum and systemic immunosuppression. Tissue damage is treated by inhibiting matrix metalloproteinases. Potential therapeutic strategies benefit from an improved understanding of ocular surface immunology, and include targeting of T-cell subsets, B-cell signalling or cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.